Consensus Conference to Assess Adjuvant Therapy for Breast Cancer

Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

BETHESDA, Md-The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

BETHESDA, Md—The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

The meeting will consider new information on chemotherapy, hormonal therapy, and other treatment aspects, including the clinical use of prognostic markers and quality-of-life issues. A panel of experts from outside NIH will make recommendations after hearing 2 days of presentations by leading researchers. The last breast cancer consensus conference on adjuvent therapy was in 1990.

Related Videos
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Experts on breast cancer
Experts on breast cancer
Related Content